Response of B-cell lymphoma to a combination of bispecific antibodies and saporin

Leukemia Research

Volumn 20, Issue 7, 1996, Pages 607-617

  French, Ruth R ^a   Bell, A J ^b   Hamblin, T J ^c   Tutt, A L ^a   Glennie, M J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Bispecific antibodies; CD22; Immunotherapy; Immunotoxin; Lymphoma; Saporin

Indexed keywords

BISPECIFIC ANTIBODY; CD22 ANTIGEN; CREATINE KINASE; IMMUNOGLOBULIN F(AB) FRAGMENT; SAPORIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; ASCITES FLUID; B CELL LYMPHOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG TOXICITY; DYSPNEA; FEMALE; FEVER; HUMAN; HUMAN CELL; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DISEASE; MALAISE; MALE; MAXIMUM PERMISSIBLE DOSE; MUSCLE WEAKNESS; MYALGIA; PANCYTOPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; SPLENOMEGALY; TUMOR CELL DESTRUCTION;

EID: 0030198903     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(96)00007-0     Document Type: Article

References (32)

1. 1. Blakey D., Wawrzynczak E. J., Wallace P. & Thorpe P. (1988) Antibody toxin conjugates: A perspective. Progr. Allergy 45, 50.
2. 2. Byers V. S. & Baldwin R. W. (1988) Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 65, 329.
3. 3. Hertler A. A. & Frankel A. E. (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin. Oncol. 7, 1932.
4. 4. Vitetta E. S., Thorpe P. E. & Uhr J. W. (1993) Immunotoxins: magic bullets or misguided missiles? Immunol. Today 14, 252.
5. 5. Spitler L. E., Del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen W. S., Rosendorf L. L., Lee H. M., Mischak R. P., Kawahata R. T., Stoudemire J. B., Fradkin L. B., Bautista E. E. & Scannon P. J. (1987) Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin A chain immunotoxin. Cancer Res. 47, 1717.
6. 6. Hertler A. A., Schlossman D. M. & Borowitz M. J. (1988) A Phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukaemia. J Biol. Response Modif. 7, 97.
7. 7. Weiner L. M., O'Dwyer J., Kitson J., Comis R. L., Frankel A. E., Bauer R. J., Konrad M. S. & Groves E. S. (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 49, 4062.
8. 8. Byers V. S., Rodvien R., Grant K., Durrant L. G., Hudson K. H., Baldwin R. W. & Scannon P. J. (1989) Phase I study of monoclonal antibody ricin A chain immunotoxin XOMAZYME-791 in patients with metastatic colon cancer. Cancer Res. 49, 6153.
9. 9. Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W. & Thorpe P. E. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51, 4052.
10. 10. Grossbard M. L., Freedman A. S., Ritz J., Coral F., Goldmacher V. S., Eliseo L., Spector N., Dear K., Lambert J. M., Blattler W. A., Taylor J. A. & Nadler L. M. (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood 79, 576.
11. 11. Falini B., Bolognesi A., Flenghi L., Tazzari P. L., Broe M. K., Stein H., Durkop H., Aversa F., Corneli P., Pizzolo G., Barbabietola G., Sabattini E., Pileri S., Martelli M. F. & Stirpe F. (1992) Response of refractory Hodgkin's disease to the monoclonal anti-CD30 immunotoxin. Lancet 339, 1195.
12. 12. Amlot P. E., Stone M. J., Cunningham D., Fay J., Newman J., Collins R., May R. D., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P. E., Uhr J. W. & Vitetta E. S. (1993) A Phase I study of an anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. Blood 82, 2624.
13. 2 antibody for the delivery of saporin in the treatment of lymphoma. J. Immunol. 141, 3662.
14. 2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res. 51, 2353.
15. 15. Bonardi M. A., French R. R., Amlot P., Gromo G., Modena D. & Glennie M. J. (1993) Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res. 53, 3015.
16. 16. Bonardi M. A., Bell A., French R. R., Gromo G., Hamblin T., Modena D., Tutt A. L. & Glennie M. J. (1992) Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int. J. Cancer (suppl) 7, 73.
17. 17. French R. R., Hamblin T. J., Bell A. J., Tutt A. L. & Glennie M. J. (1995) Treatment of B-cell lymphomas with a combination of bispecific antibodies and saporin. Lancet 346, 223.
18. 18. Glennie M. J. & French R. R. (1995) Targeting drugs, toxins and radionuclides with bispecific antibodies. In Bispecific Antibodies (Fanger M. J., Ed.), pp. 107-120. Molecular Biology Intelligence Unit, R. G. Landes Company, Austin, Texas, U.S.A.
19. 19. Stansfeld A. G., Diebold J., Noel H., Kapanci Y., Rilke F., Kelenyi G., Sundstrom C., Lennert K., Van Unnik J. A., Mioduszewska O. & Wright D. H. (1988) Updated Kiel classification for lymphoma. Lancet 1, 8580, 292.
20. 20. Reynolds W. M., Williamson A. M., Smith G. J. & Lane A. C. (1992) A simple technique for the determination of kappa and lambda immunoglobulin light chain expression by B cells in whole blood. J. Immunol. Methods 151, 123.
21. 21. Stirpe F., Gasperi-Campani G., Barbieri L., Falasca A., Abbondanza A. & Stevens W. A. (1983) Ribosome inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L (corn cockle) and of Asparagus officinalis (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem. J. 216, 617.
22. 2 antibody containing thioether-linked Fab′γ fragments. J. Immunol. 139, 2367.
23. 3 antibody derivatives. In Tumour Immunobiology, a Practical Approach (Gallagher G., Rees R. C. & Reynolds C. W., Eds), pp. 225-244. IRL Press at Oxford University Press, Oxford, U.K.
24. 24. Moldenhauer G., Dorken B., Schwartz R., Pezzutto A. & Hammerling G. J. (1986) Characterization of human B lymphocyte specific antigen defined by monoclonal antibodies HD6 and HD39. In Leukocyte Typing II, Vol. 2: Human B Lymphocytes (Reinherz B. F., Haynes B. F., Nadler L. M. & Bernstein I. D., Eds), pp. 97-107. Springer, New York.
25. 25. Mason D. Y., Stein H., Gerdes J., Pulford K. A. F., Ralfkiaer E., Falini B., Erber W. N., Micklem K. & Gatter K. C. (1987) Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69, 836.
26. 26. Hamblin T. J., Cattan A. R., Glennie M. J., Mackenzie M. R., Stevenson F. K., Watts H. F. & Stevenson G. T. (1987) Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 69, 790.
27. 27. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48. Geneva, Switzerland, WHO (1979).
28. 28. Grossbard M. L., Freedman A. S., Kinsella J. M., et al. (1991) Immunotherapy with anti-B4-blocked ricin (anti-B4-BR): Phase I trials of continuous infusion in patients with B-cell neoplasms. Blood 78, 174.
29. 29. Ghetie M. A., Uhr J. W. & Vitetta E. S. (1991) Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. Cancer Res. 51, 1482.
30. 30. Stirpe F., Derenzini M., Barbieri L., Farabegoli F., Brown A. N. F., Knowles P. P. & Thorpe P. E. (1987) Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein from Saponaria officinalis. Virchows Arch. B. Zellpathol. 53, 259.
31. 31. Glennie M. J., McBride H. M., Stirpe F., Thorpe P. E., Worth A. T. & Stevenson G. T. (1987) Emergence of immunoglobulin variants following treatment of a B-cell leukemia with an immunotoxin composed of anti-idiotype and saporin. J. Exp. Med. 166, 43.
32. 32. French R. R., Penney C. A., Browning A. C., Stirpe F., George A. J. T. & Glennie M. J. (1995) Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br. J. Cancer 71, 986.